tbuckley/cabot-search huggingface dataset:
SURVIVAL IN CLINICALLY SIGNIFICANT TRICUSPID REGURGITATION PATIENTS WITH AND WITHOUT HEART FAILURE: EVIDENCE FROM OPTUM'S INTEGRATED DATABASES
Authors: Colin M. Barker, David Patrick Cork, Hirsch Mehta, Peter McCullough, William Irish, Joanna Van Houten, Candace Gunnarsson, Sarah Mollenkopf, Patrick Verta
Journal: Journal of the American College of Cardiology (2020)
HSR20-096: Budget Impact Analysis of Avelumab Plus Axitinib for the First-Line Treatment of Patients With Advanced Renal Cell Carcinoma
Authors: Frank Xiaoqing Liu, Kirstin Heinrich, Catarina Neves, Ying Zheng, Adam Kasle
Journal: Journal of the National Comprehensive Cancer Network (2020)

"HSR20-096: Budget Impact Analysis of Avelumab Plus Axitinib for the First-Line Treatment of Patients With Advanced Renal Cell Carcinoma" published on 20 Mar 2020 by National Comprehensive Cancer Network.
Triweekly carboplatin alone in the treatment of oropharyngeal carcinoma with definitive concurrent chemoradiation: Outcomes of 120 unselected patients and a comparison to the RTOG 0129 regimen results.
Authors: Shawn Iganej, Gary L. Buchschacher, Iman A. Abdalla
Journal: Journal of Clinical Oncology (2012)

e16031 Background: In 2002, due to the significant toxicities associated with triweekly high-dose cisplatin, we decided to routinely use triweekly carboplatin in the treatment of locally advanced head and neck cancer patients as our standard definitive concurrent chemoradiation drug, the outcomes of which are reported here. Methods: From August of 2002 through May of 2009, newly diagnosed patients with stage III (22%) or IVA/B (78%) oropharyngeal squamous carcinoma were treated with carboplatin (AUC=5) x 3 on days 1, 22 and 43 along with concurrent conventional RT (N=67) or IMRT (N=53) to 70 Gy. Individuals treated with induction chemotherapy or definitive surgery of any kind prior to concurrent chemoradiation, and surviving/recurrence-free patients with less than 24 months of follow-up were excluded, leaving 120 patients for this analysis. The median age was 58 (range 42-85). Feeding tubes were not placed prophylactically. Planned post chemoRT neck dissections were not performed. HPV/P16 status was not determined in any patients prior to treatment. Seventy-one patients (59%) had a significant history of tobacco use, 38 of whom were current smokers. Results: With a median follow-up of 64 months (range 32-108) for surviving patients, 15 (12.5%) had a loco-regional recurrence (LR), and a total of 9 patients (7.5%) failed distantly, including one with simultaneous LR. Only 26 (22%) patients required feeding tubes during or shortly after (&lt; 90 days) chemoRT; 90% received 3 cycles of carboplatin and planned RT dose was delivered in 98%. The 3-year loco-regional control and overall survival rates for the entire group were 88% and 82%, respectively; these rates for 92 patients eligible for RTOG 0129 (T2N2-3, T3-4 any N) were 86% and 77%. At last follow-up, only 3% were feeding-tube dependent. Conclusions: This first ever report of concurrent triweekly carboplatin alone with radiotherapy at a large U.S. institution for locally advanced oropharyngeal carcinoma suggests that it is better tolerated and more feasible than concurrent triweekly high-dose cisplatin, with similar/favorable disease control and survival rates.
The clinical significance of ephrin receptors expression in non-small cell lung cancers.
Authors: Nikolaos Tsoukalas, Constantinos Giaginis, Nicolaos Kavantzas, Paraskevi Alexandrou, Evangelos Bournakis, Efstratios Patsouris, Stamatios Theocharis
Journal: Journal of Clinical Oncology (2013)

e22160 Background: Ephrin receptors (Ephs) are frequently overexpressed in a wide variety of human malignant tumors, being associated with tumor growth, invasion, metastasis and angiogenesis. The present study aimed toevaluate the clinical significance of Eph-A1, -A4, -A5 and -A7 protein expression in non-small cell lung cancers (NSCLC). Methods: Eph-A1, -A4, -A5 and -A7 protein expression was assessed immunohistochemically in tissue microarrays of 88 surgically resected NSCLC cases and was analyzed in relation with clinicopathological characteristics and patients’ survival. Results: Elevated Eph-A4 expression was significantly associated with earlier or lower stages and histopathological presence of inflammation (p=0.047 and p=0.026, respectively). Elevated Eph-A7 expression was significantly associated with patients’ age, presence of fibrosis and smaller tumor size (p=0.036, p=0.029 and p=0.018, respectively). NSCLC patients with elevatedEph-A4, -A5 or -A7 expression presented significantly longer overall survival times compared to those with reduced Eph-A4, -A5 or -A7 expression (log-rank test, 0=0.019, p=0.006 and p=0.012, respectively). Eph-A4, -A5 and -A7 expression were identified as independent prognostic factors of patients’ survival after adjustment for histopathological type and stage and performance status (Cox-regression analysis, p=0.022, p=0.033 and p=0.037, respectively). Conclusions: The present study supported evidence that Ephs may play a role in lung cancer progression, reinforcing their utility as clinical biomarkers for patients’ management and prognosis, as well as targets for potential therapeutic intervention in the future.
Check Engine Light
Authors: Heather Finlay-Morreale
Journal: JAMA Neurology (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
IN SILICO VERSUS CLINICAL CRITERIA FOR THE DIAGNOSIS OF FAMILIAL HYPERCHOLESTEROLEMIA: A COMPARATIVE EVALUATION
Authors: Mohammad Salman Sheikh, Sakshi Yadav, Molly M. Thompson, Zahara Meghji, Katherine Wilemon, Raheel Islam, Nageshwara Gullapalli, Jim Metcalf, Anthony Slonim, Joe Grzymski, Christopher J. Rowan
Journal: Journal of the American College of Cardiology (2020)
CHAMBER REMODELING AFTER SUCCESSFUL CARDIOVERSION FOR ATRIAL FIBRILLATION AND IMPACT ON TRICUSPID REGURGITATION
Authors: Laurie Soulat-Dufour, Ariel Cohen, Amita Singh, Jeanne M. DeCara, Victor Mor-Avi, Parker Ward, Eric Kruse, Gaurav A. Upadhyay, Zaid Aziz, Andrew D. Beaser, Michael Broman, Roderick Tung, Sylvie Lang, Roberto Lang, Karima Addetia
Journal: Journal of the American College of Cardiology (2020)
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer (TNBC) in a Peruvian institute.
Authors: Katerin Ingrid Rojas
Journal: Journal of Clinical Oncology (2013)

e12038 Background: TNBC is defined by the lack of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 expressions (HER-2). This molecular classification is an excellent prognostic and predictive method in breast cancer (BC). This is an aggressive malignancy with a poor prognosis despite the high rates of response to chemotherapy. Methods: Observational descriptive. We included 165 patients with TNBC stage I-III who received neoadjuvant chemotherapy at National Cancer Institute of Peru from 2000 to 2010. Clinical and pathologic complete response rates, survival measurements, and organ-specific rates of relapse were evaluated. Overall survival (OS) and disease free survival (DFS). Results: The mean age at diagnosis was 48.6 years (range, 24-74 years). The mean size tumor before treatment was 7.7 cm (range, 1-25 cm). One hundred and fifty seven patients (95.2%) had ductal carcinoma. One hundred twenty nine cases (78.2%) were histological grade III. According to T stage, 65 (39.4%) T3 and 83 (50.3%) T4. Thirty four cases (20.6%) were N0. Seventy three patients (44.2%) received AC-Paclitaxel schedule. Thirty four patients (20.6%) had CR to neoadjuvant chemotherapy. There is a significant difference about tumor size before and after neoadjuvant treatment (7.7 vs. 3.6, p&lt;0.05).OS at 5 years for patients with residual disease was 83.5%. In patients with complete response the DFS at 5 years was 55.1%. Locoregional and lung were the most frequent site of recurrence (15.8%) and (13.9%) respectively. According Miller and Paine to grade tumor response, 17 patients(10.3%) I ,33 (20.0%) II, 33 (20.0%) III, 20 (12.1%) IV and 27 (16.4%) V. Node response, 20 patients (12.1%) had type A, 51 (30.9%) type B, 23 (13.9%) type C and 34 (20.6%) type D. Conclusions:These results suggest that most TNBC are in accordance with literature data, especially concerning young age at diagnosis, high grade tumors, advances locally stage at diagnosis, and short time to relapse, high response rate to chemotherapy and excellent OS and DFS. We know it is a heterogeneous disease; however the clinical characteristics still play an important role to predict treatment response and survival.
Serine Catabolism Feeds NADH when Respiration Is Impaired
Authors: Lifeng Yang, Juan Carlos Garcia Canaveras, Zihong Chen, Lin Wang, Lingfan Liang, Cholsoon Jang, Johannes A. Mayr, Zhaoyue Zhang, Jonathan M. Ghergurovich, Le Zhan, Shilpy Joshi, Zhixian Hu, Melanie R. McReynolds, Xiaoyang Su, Eileen White, Raphael J. Morscher, Joshua D. Rabinowitz
Journal: Cell Metabolism (2020)
A NOVEL SUBSET OF HYPERTROPHIC CARDIOMYOPATHY PATIENTS CHARACTERIZED BY ASSOCIATION WITH TAKOTSUBO-LIKE LV BALLOONING AND HOSPITAL ADMISSION
Authors: Katherine N. Riedy, Harmony Reynolds, Barry P. Rosenzweig, Daniele Massera, Muhamed Saric, Daniel Swistel, Monica Ahluwalia, Milla Arabadjian, Maria Defonte, Alexandra Stepanovic, Stephanie Serrato, Yuhe Xia, Hua Zhong, Mark Sherrid
Journal: Journal of the American College of Cardiology (2020)
IMPORTANCE OF PAROXYSMAL ATRIAL FIBRILLATION FOR THE PREVENTION OF EMBOLIC STROKE IN HYPERTROPHIC CARDIOMYOPATHY
Authors: Junya Komatsu, Takako Fujita, Yuki Nishimura, Ryuichirou Imai, Yoko Nakaoka, Koji Nishida, Satoshi Yamamoto, Shuichi Seki, Syouichi Kubokawa, Kazuya Kawai, Naohisa Hamashige, Yoshinori L. Doi
Journal: Journal of the American College of Cardiology (2020)
IMPACT OF HIGH LIPOPROTEIN(A) LEVELS ON PLATELET AGGREGABILITY IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE
Authors: Rocío Salsoso, Talia Dalçóquio, Remo Furtado, Andre Franci, Carlos Barbosa, Paulo Genestreti, Mayara Reis Cardoso Ferreira, Celia Strunz, Luciano Baracioli, Raul Cavalcante Maranhão, Jose Carlos Nicolau
Journal: Journal of the American College of Cardiology (2020)
Evaluation of dickkopf-1 (Dkk-1) expression in non-small cell lung, esophageal, and gastric cancer.
Authors: Haeseong Park, Andrew Stewart Poklepovic, Jorge Almenara, Cynthia Sirard, Junqi Qian, Celeste N. Powers, Steven R. Grossman
Journal: Journal of Clinical Oncology (2013)

e22203 Background: Dkk-1 is an inhibitor of the canonical Wnt/β-catenin signaling pathway. Inhibition of Wnt pathway results in the stabilization of β-catenin, leading to target gene expression such as cyclin D1, c-myc, VEGF and other factors associated with cell growth. Elevated levels of serum Dkk-1 in a variety of tumor types are well established, and are hypothesized to have a negative prognostic value. Tumor tissue expression of Dkk-1 has not been systematically examined. We evaluated Dkk-1 expression in various tumors. Methods: Utilizing an anonymous banked tumor repository, we identified 119 patient samples (NSCLC (squamous, n=19; adenocarcinoma, n=47), esophageal (squamous, n=15; adenocarcinoma, n=17) and gastric (n=20)). Immunohistochemical (IHC) staining was performed using commercially available antibodies. One pathologist evaluated all slides using IHC staining quantification on a 4-point scale (0, 1+, 2+, 3+). Results: Dkk-1 expression is more pronounced in tumor tissues than peritumoral normal tissues of lung and esophagus. Unexpectedly, Dkk-1 expression is seen in two staining patterns, perinuclear and cytoplasmic that varied by primary location and histology. Conclusions: Elevated Dkk-1 expression is demonstrated in lung, esophageal and gastric cancer regardless of histology. All except squamous cell lung express perinuclear Dkk-1 more frequently than cytoplasmic pattern. Additional studies are needed to understand significance of these patterns and potentially define Dkk-1 as a novel therapeutic target in these malignancies. [Table: see text]
Influence of BMI on outcomes of high-dose cytarabine and mitoxantrone induction therapy for AML.
Authors: Mansoor Burhani, Manish J. Dave, Parameswaran Venugopal, Melissa L. Larson
Journal: Journal of Clinical Oncology (2013)

7106 Background: Acute Myeloid Leukemia (AML) affects thousands of Americans every year. With approximately 35.7% of the U.S. adult population being obese, it is important to understand how a patient’s BMI can affect their outcome with AML treatment. This study evaluates a high-dose cytarabine and mitoxantrone induction regimen, and the results are examined to determine the effect of BMI on outcome, in terms of induction response and survival. Methods: Eighty nine patients were treated with a High Dose Cytarabine and Mitoxantrone regimen from 2008-2012. Two doses of cytarabine 3 gm/m 2 were given 12 hours apart followed by one dose of mitoxantrone 30 mg/m 2 on days 1 and 5. All patients were dosed based on their actual body weight. Before treatment began, the BMI for each of the patients was recorded. The outcome data was collected and analyzed. Results: Of the 89 patients, 22 patients were normal, 33 overweight, and 34 obese. The BMI readings are based on the definitions established by the WHO. The overall CR rate for all 89 patients was 65%. The CRR for normal patients was 77%, 55% for overweight patients, and 68% for obese patients. 62 (70%) patients remain alive: 73% of normal patients, 58% of overweight, and 79% of obese. 17 of patients never achieved remission, even after multiple induction courses: 2 (9%) in the normal group, 10 (30%) in the overweight group, and 5 (15%) in the obese group. Of the responders, 35% of normal patients had a relapse, 30% in the overweight group, and 21% in the obese group with median relapse free survival of 8 months, 10 months and 6 months, respectively. Conclusions: Patients with a healthier BMI were more likely to respond to induction therapy with high-dose cytarabine and mitoxantrone. However, there was no difference in relapses amongst the groups. Patients who did not respond initially were unlikely to respond to other treatments. Therefore, using actual weight to determine dosing in AML induction therapy is the appropriate strategy.
Conquering lung cancer: current status and prospects for the future
Authors: R. Pirker
Journal: Pulmonology (2020)

Lung cancer is a major global health problem. Several strategies are required to conquer this cancer. Stricter implementations of tobacco control measures are necessary. Early detection programs should be implemented to decrease lung cancer mortality. Although chemotherapy remains a cornerstone of treatment, targeted therapies and immune checkpoint inhibitors improved treatment of metastatic cancers and are hoped to improve outcome of adjuvant and induction therapies. Novel immunotherapy approaches hold great promise. Better understanding of the molecular biology of lung cancer should lead to rational drug design.
Towards a quantum-like cognitive architecture for decision-making
Authors: Catarina Moreira, Lauren Fell, Shahram Dehdashti, Peter Bruza, Andreas Wichert
Journal: Behavioral and Brain Sciences (2020)

We propose an alternative and unifying framework for decision-making that, by using quantum mechanics, provides more generalised cognitive and decision models with the ability to represent more information than classical models. This framework can accommodate and predict several cognitive biases reported in Lieder & Griffiths without heavy reliance on heuristics nor on assumptions of the computational resources of the mind.
Heart Failure Associated With the Epidermal Growth Factor Receptor Inhibitor Osimertinib
Authors: Andrew J. Piper-Vallillo, Daniel B. Costa, Marwa A. Sabe, Aarti Asnani
Journal: JACC CardioOncology (2020)

Incorporation of molecular targeted therapies into the care of patients with sensitizing mutations has driven significant improvements in outcomes in non-small cell lung cancer (NSCLC). Epidermal growth factor receptor ( EGFR )-mutant lung cancer includes the greatest percentage of these cases, and
DIRECT CONVERSION OF ADULT HUMAN FIBROBLASTS INTO AUTHENTIC ENDOTHELIAL CELLS
Authors: Jung-kyu Han, Youngchul Shin, Min-hwan Ryan Sohn, Saet-Byeol Choi, Dasom Shin, Jong-yeon Shin, Jeong-sun Seo, Hyo-Soo Kim
Journal: Journal of the American College of Cardiology (2020)
Pilot study measuring transepidermal water loss (TEWL) in children suggests trilipid cream is more effective than a paraffin‐based emollient
Authors: Sayantani Sindher, Shifaa S. Alkotob, Melanie N. Shojinaga, Helen A. Brough, Henry T. Bahnson, Susan Chan, Gideon Lack, Donald Y. M. Leung, Kari C. Nadeau
Journal: Allergy (2020)
MULTICENTER CLINICAL EVALUATION OF A PIEZORESISTIVE-SENSOR-EQUIPPED RAPID-EXCHANGE PRESSURE MICROCATHETER SYSTEM FOR FRACTIONAL FLOW RESERVE MEASUREMENT (SUPREME STUDY)
Authors: Chenguang Li, Junqing Yang, Shaohong Dong, Liang Dong, Jiyan Chen, Li Shen, Changling Li, Huadong LIU, Xinyang Hu, William Kongto Hau, Allen Jeremias, Jianan Wang, Junbo Ge
Journal: Journal of the American College of Cardiology (2020)
Association of Opioid Use With Pain and Satisfaction After Dental Extraction
Authors: Romesh P. Nalliah, Kenneth R. Sloss, Brooke C. Kenney, Sarah K. Bettag, Shernel Thomas, Kendall Dubois, Jennifer F. Waljee, Chad M. Brummett
Journal: JAMA Network Open (2020)

<h3>Importance</h3> Dentists commonly prescribe opioids to relieve pain after tooth extraction. Understanding the differences in patient-reported outcomes between opioid users and nonusers could encourage the adoption of more conservative and appropriate prescribing practices in dental medicine. <h3>Objective</h3> To evaluate whether pain and satisfaction scores reported by patients who used opioids after tooth extraction were similar to the levels reported by patients with no opioid use. <h3>Design, Setting, and Participants</h3> This quality improvement study was conducted in the 14 dental clinics of the University of Michigan School of Dentistry. Eligible adult patients of these clinics who underwent routine or surgical extractions between June 1, 2017, and December 31, 2017, were contacted by telephone within 6 months of the procedure. Patients were surveyed about the type of extraction, use of prescription opioid (if given), use of nonopioid analgesics, pain levels, and satisfaction with care after the procedure. Data analysis was conducted from February 1, 2018, to July 31, 2018. <h3>Main Outcomes and Measures</h3> The primary outcome was self-reported pain as assessed by the question, "Thinking back, how would you rate your pain in the first week after your dental procedure?" with a 4-point pain scale of no pain, minimal pain, moderate pain, or severe pain. Secondary outcomes included self-reported satisfaction with care as assessed by a Likert scale ranging from 1 to 10, in which 1 was extremely dissatisfied and 10 was extremely satisfied. <h3>Results</h3> The final cohort comprised 329 patients, of whom 155 (47.1%) underwent surgical extraction (mean [SD] age, 41.8 [18.1] years; 80 [51.6%] were men) and 174 (52.9%) underwent routine extraction (mean [SD] age, 52.4 [17.9] years; 79 [45.4%] were men). Eighty patients (51.6%) with surgical extraction and 68 (39.1%) with routine extraction used opioids after their procedure. In both extraction groups, patients who used opioids reported higher levels of pain compared with those who did not use opioids (surgical extraction group: 51 [64.6%] vs 34 [45.3%],<i>P</i> &lt; .001; routine extraction group: 44 [64.8%] vs 35 [33.1%],<i>P</i> &lt; .001). No statistically significant difference in satisfaction was found between groups after surgical extraction (median [interquartile range] scores: 9 [7-10] for nonopioid group vs 9 [8-10] for opioid group) and routine extraction (median [interquartile range] scores: 10 [8-10] for nonopioid group vs 9 [7-10] for opioid group). <h3>Conclusions and Relevance</h3> This study found that patients who used opioids after tooth extraction reported significantly higher levels of pain compared with nonusers, but no difference in satisfaction was observed.
ASSOCIATION BETWEEN HOMEOSTATIC MODEL ASSESSMENT OF INSULIN RESISTANCE, GLYCOSYLATED HEMOGLOBIN AND NON-CALCIFIED CORONARY BURDEN IN PSORIASIS
Authors: Raja Zaghlol, Amit Dey, Mithun Devraj, Heather Teague, Justin Rodante, Martin Playford, Marcus Y. Chen, Nehal Mehta
Journal: Journal of the American College of Cardiology (2020)
What is the role of QTc prolongation assessment in new drugs development phase I oncology trials?
Authors: G. Curigliano, C. Cipolla, C. Sessa, C. Noberasco, T. De Pas, N. Colombo, G. Spitaleri, C. Putzu, A. Milani, F. De Braud
Journal: Journal of Clinical Oncology (2006)

2006 Background: QT interval prolongation associated with “torsades de pointes” (TdP) has been a common cause of withdrawal from the market for several promising drugs. We determined the degree of QT prolongation in patients treated within a phase I study with a thioxanthone derivative known to have arrhythmogenic potential. Methods: Clinical data and serial ECGs from 31 patients with advanced tumors who received 86 courses of investigational drug were prospectively reviewed. The drug has been administered intravenously over 24 hours every 3 weeks. Patients have been on a 24 hour Holter monitor until 24 hours after infusion was complete. Three baseline ECGs were done and compared to those every 6 hours during therapy and once 6 hours after the infusion was complete. ECGs were read at a central lab according to a standard protocol. All QT measurements were then corrected for heart rate (QTc) using Bazett’s formula (QTc = QT interval divided by the square root of the R-R interval). Results: Overall,843 ECG tracings were obtained, all evaluable for analysis. No basal ECG showed significant abnormalities. Prolonged QT intervals developed in 2 patients without clinical symptoms (1 patient had intervals 500 milliseconds).In both cases it was associated with the maximum concentration of the drug. Compared with baseline, the QTc interval was prolonged by 30 to 60 milliseconds in 20% of total tracings, and by more than 60 milliseconds in 2% of ECGs. In patients receiving multiple courses, QTc intervals returned to pretreatment levels before the second course. Conclusions: The assessment of QTc prolongation was a major effort in this study but produced an accurate information about such event. In phase I study such an effort is justified when arrhythmogenicity is suspected. The timing of collection of ECGs should be guided by the available preclinical information about the pharmacokinetic profile of the drug. Nevertheless uncertainty remains regarding the specific relationship between the degree of QT prolongation and the risk of life-threatening arrhythmias. The decision to use the drug ultimately has to be based on an estimation of the perceived risk relative to expected benefits for patients. No significant financial relationships to disclose.